← Home / ALNYLAM PHARMACEUTICALS, INC. (ALNY)
Stock Analysis

ALNYLAM PHARMACEUTICALS, INC. (ALNY)

ALNY
ALNY · Healthcare • Biotechnology
236.22 +3.02%
Track ALNY in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when ALNY price is:
52W Range Position
11%
LOWMIDHIGH
Trend
Vulnerable
Momentum
Neutral
Updated: 2026-08-23 19:48 UTC
WOI Investment Thesis
Vulnerable
Watch confirmation and structural levels before acting.
⚖️
✓
Fundamentals
Weak / Positive
✓
Price Structure
Vulnerable
•
Momentum
Neutral
×
Current Resistance
Below Resistance
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
No reliable structural support level is currently available.
Not available
↗
Break Above
Primary setup confirms above this trigger.
359.10
🎯
Next Objective
No defined objective is currently available for the primary downtrend breakout.
Not available
×
Thesis Break
No setup-specific invalidation level is currently defined.
Not available
Recent Company Events
SEC VERIFIED
Latest material filings
JUL
30
●
Financial Results
HIGH
Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress
(Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2026, and reviewed recent business highlights.
8-K Filing • SEC EDGAR
MAY
27
●
Management / Board
MEDIUM
ALNY board and management update
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.
8-K Filing • SEC EDGAR
APR
30
●
Financial Results
HIGH
Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress
(Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2026, and reviewed recent business highlights.
8-K Filing • SEC EDGAR
What's Driving ALNY?
▲ Technical confirmation is pending
Momentum is Neutral. Watch Above 359.10 for setup confirmation. No reliable structural risk level is currently available.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
A technical structure is developing but has not yet reached confirmed active status.
Downtrend Structure
Downtrend line not broken yet · score 0
Trigger
359.10
RSI(14)
46.7
Price Chart
ALNY — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-08-21
Premium
Premium valuation
The stock trades at elevated sales or book multiples; quality must justify the price.
Market Cap
$30.7B
Company size
EV
$30.4B
Debt-adjusted value
P/E
39.9
Premium
P/S
6.4
Balanced
P/B
22.6
Very high
EV/Sales
6.3
Balanced
EV/EBIT
35.3
Premium
P/FCF
113.0
Very high
FCF Yield
0.89%
Cash return
Not financial advice
Business Lens
Financial context is mixed
Financial quality is mixed, with cash flow or balance sheet items requiring closer monitoring.
↗
Revenue Growth
Weak
●
Profitability
Positive
≈
Cash Flow
Healthy
⚖
Balance Sheet
Stretched
💵 Revenue
1.29B
↘ Weak
📈 Net Income
164.49M
↗ Positive
🧮 EPS (Basic)
1.23
↗ Positive
ALNYLAM PHARMACEUTICALS, INC.
Healthcare • Biotechnology
You Might Also Like